Topline data results from the pivotal STRIDE study are expected in December 2023 IRVINE, Calif., Nov. 13, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023… Continue reading Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
